Among bioactive peptides, GHK Cu peptide (glycyl-L-histidyl-L-lysine-copper) has experienced a surge of interest in both consumer products and scientific literature
Both classifications carry prohibition at all times, in and out of competition, and substances under both sections are non-Specified Substances under the WADA Code
Topical and Injectable GHK-Cu Routes Compared Topical GHK-Cu has published cosmetic, wound, and trial-context evidence, while injectable GHK-Cu lacks an FDA-approved dosing label and is specifically discussed by FDA in relation to compounded injectable safety concerns [2], [3], [7], [8]
Snchez A, Vzquez A
Not intended for human consumption, clinical use, or as a drug, food, cosmetic, or medical device